{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:19:26Z","timestamp":1757618366033,"version":"3.44.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40262-025-01509-0","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T09:16:55Z","timestamp":1750670215000},"page":"1217-1230","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics of Binimetinib in Participants with Hepatic Impairment"],"prefix":"10.1007","volume":"64","clinical-trial-number":[{"clinical-trial-number":"nct02050815","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1174-966X","authenticated-orcid":false,"given":"Joseph","family":"Piscitelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lance","family":"Wollenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renae","family":"Chavira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Del Frari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micaela B.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"1509_CR1","unstructured":"US Food and Drug Administration. Mektovi: Highlights of prescribing information. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210498lbl.pdf."},{"issue":"5","key":"1509_CR2","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/bjc.2017.10","volume":"116","author":"JC Bendell","year":"2017","unstructured":"Bendell JC, et al. A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1\/2 inhibitor. Br J Cancer. 2017;116(5):575\u201383.","journal-title":"Br J Cancer"},{"issue":"1","key":"1509_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.70061","volume":"13","author":"D Huynh","year":"2025","unstructured":"Huynh D, et al. The absorption, distribution, metabolism, and excretion of binimetinib following a single oral dose of [(14)C]Binimetinib 45 mg in healthy male participants. Pharmacol Res Perspect. 2025;13(1):e70061.","journal-title":"Pharmacol Res Perspect"},{"key":"1509_CR4","unstructured":"MEKTOVI (binimetinib) tablets, Full Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/210498s001lbl.pdf. Accessed 1 June 2024."},{"issue":"3","key":"1509_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00280-024-04676-2","volume":"94","author":"J Piscitelli","year":"2024","unstructured":"Piscitelli J, et al. Evaluation of the effect of modafinil on the pharmacokinetics of encorafenib and binimetinib in patients with BRAF V600-mutant advanced solid tumors. Cancer Chemother Pharmacol. 2024;94(3):337\u201347.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1509_CR6","unstructured":"US Food and Drug Administration. Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling."},{"issue":"14_suppl","key":"1509_CR7","doi-asserted-by":"publisher","first-page":"6051","DOI":"10.1200\/jco.2004.22.90140.6051","volume":"22","author":"H Patel","year":"2004","unstructured":"Patel H, Egorin MJ, Remick SC, et al. Comparison of Child-Pugh(CP) criteria and NCI organ dysfunction working group (NCI-ODWG) criteria for hepatic dysfunction (HD): implications forchemotherapy dosing. J Clin Oncol. 2004;22(14_suppl):6051.","journal-title":"J Clin Oncol"},{"key":"1509_CR8","unstructured":"NCI. Protocol Template for Organ Dysfunction Studies. 2019."},{"issue":"1","key":"1509_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/jcph.1702","volume":"61","author":"M Elmeliegy","year":"2021","unstructured":"Elmeliegy M, et al. Discordance between Child-Pugh and National Cancer Institute Classifications for Hepatic Dysfunction: Implications on Dosing Recommendations for Oncology Compounds. J Clin Pharmacol. 2021;61(1):105\u201315.","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"1509_CR10","first-page":"939","volume":"12","author":"MM Ramirez-Mejia","year":"2024","unstructured":"Ramirez-Mejia MM, et al. The multifaceted role of bilirubin in liver disease: a literature review. J Clin Transl Hepatol. 2024;12(11):939\u201348.","journal-title":"J Clin Transl Hepatol"},{"issue":"27","key":"1509_CR11","doi-asserted-by":"publisher","first-page":"17960","DOI":"10.1016\/S0021-9258(17)32403-1","volume":"269","author":"PJ Bosma","year":"1994","unstructured":"Bosma PJ, et al. Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem. 1994;269(27):17960\u20134.","journal-title":"J Biol Chem"},{"issue":"4","key":"1509_CR12","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00280-018-3517-8","volume":"81","author":"AB El-Khoueiry","year":"2018","unstructured":"El-Khoueiry AB, et al. Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer. Cancer Chemother Pharmacol. 2018;81(4):659\u201370.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"19","key":"1509_CR13","doi-asserted-by":"publisher","first-page":"5102","DOI":"10.1158\/1078-0432.CCR-19-3550","volume":"26","author":"RJ Sullivan","year":"2020","unstructured":"Sullivan RJ, et al. A Phase Ib\/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAF(V600E\/K) -mutant Solid Tumors. Clin Cancer Res. 2020;26(19):5102\u201312.","journal-title":"Clin Cancer Res"},{"key":"1509_CR14","unstructured":"US Food and Drug Administration. Camptosar: Highlights of Prescribing Information."},{"key":"1509_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107689","volume":"218","author":"JO Miners","year":"2021","unstructured":"Miners JO, et al. Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping. Pharmacol Ther. 2021;218: 107689.","journal-title":"Pharmacol Ther"},{"issue":"4","key":"1509_CR16","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/bcpt.12929","volume":"122","author":"L Xiao","year":"2018","unstructured":"Xiao L, et al. New insights into SN-38 glucuronidation: evidence for the important role of UDP glucuronosyltransferase 1A9. Basic Clin Pharmacol Toxicol. 2018;122(4):424\u20138.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"12","key":"1509_CR17","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1158\/1078-0432.CCR-05-2152","volume":"12","author":"LJ Schaaf","year":"2006","unstructured":"Schaaf LJ, et al. Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction. Clin Cancer Res. 2006;12(12):3782\u201391.","journal-title":"Clin Cancer Res"},{"key":"1509_CR18","unstructured":"US Food and Drug Administration. Lamictal: Highlights of Prescribing Information."},{"issue":"4","key":"1509_CR19","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1124\/dmd.114.062877","volume":"43","author":"G Margaillan","year":"2015","unstructured":"Margaillan G, et al. Quantitative profiling of human renal UDP-glucuronosyltransferases and glucuronidation activity: a comparison of normal and tumoral kidney tissues. Drug Metab Dispos. 2015;43(4):611\u20139.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"1509_CR20","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1124\/dmd.111.043984","volume":"40","author":"KL Gill","year":"2012","unstructured":"Gill KL, Houston JB, Galetin A. Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin. Drug Metab Dispos. 2012;40(4):825\u201335.","journal-title":"Drug Metab Dispos"},{"issue":"18","key":"1509_CR21","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1056\/NEJM199511023331802","volume":"333","author":"PJ Bosma","year":"1995","unstructured":"Bosma PJ, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert\u2019s syndrome. N Engl J Med. 1995;333(18):1171\u20135.","journal-title":"N Engl J Med"},{"key":"1509_CR22","doi-asserted-by":"crossref","unstructured":"Correction to: Abstracts for the Ninth American Conference on Pharmacometrics (ACoP9). J Pharmacokinet Pharmacodyn, 2021; T-051: p. 613-614.","DOI":"10.1007\/s10928-021-09767-8"},{"key":"1509_CR23","unstructured":"US Food and Drug Administration. Mektovi: Multidisciplinary Review."},{"key":"1509_CR24","unstructured":"Del Frari L., G.N., Claudia Jomphe, JF Marier, Wollenberg L., Reddy M., Litwiler K., Didier E., Population modelling and simulations of binimetinib pharmacokinetics in subjects with hepatic impairment to explore optimal dosing regimen using total and unbound binimetinib exposures. Population Approach Group Europe, 2019."},{"issue":"4","key":"1509_CR25","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/cpt.2505","volume":"112","author":"DZ Yang","year":"2022","unstructured":"Yang DZ, et al. Analysis of US Food and Drug Administration Oncology approvals on the characterization of hepatic impairment effect and dosing recommendations. Clin Pharmacol Ther. 2022;112(4):782\u201390.","journal-title":"Clin Pharmacol Ther"},{"key":"1509_CR26","unstructured":"European Medicines Agency. Mektovi: EPAR- Product Information."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01509-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01509-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01509-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T21:39:33Z","timestamp":1757194773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01509-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1509"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01509-0","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"type":"print","value":"0312-5963"},{"type":"electronic","value":"1179-1926"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"assertion":[{"value":"13 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was sponsored by Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"J.P., M.B.R., L.W., R.C., and E.H. are employees of Pfizer and hold Pfizer stock. L.D.F. is an employee of Pierre Fabre Medicament.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"These studies were conducted in compliance with the ethical principles originating in or derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. In addition, all local regulatory requirements were followed, particularly those afording greater protection to the safety of trial participants. An institutional review board approved the protocols, and all participants gave written informed consent. This trial was registered on ClinicalTrials.gov: NCT02050815.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All participants provided written informed consent before undergoing any study procedures.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication and Code availability"}},{"value":"The analyses in this paper were based on a data cut-off of 07\/19\/2017. Upon reasonable request and participant to review, Pfizer will provide the data that support the findings of this study. Participant to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual de-identified participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines, and medical devices (1) for indications that have been approved in the USA and\/or EU or (2) in programs that have been terminated (that is, development for all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. See  for more information. Data may be requested from Pfizer trials 24 months after study completion. The de-identified participant data will be made available, via a secure portal, to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply. To gain access, data requestors must enter into a data access agreement with Pfizer.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"J.P., M.B.R., L.W., R.C., E.H., and L.D.F designed and carried out the research, analyzed the data, and wrote the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}